Denmark's Forward Pharma to launch IP attack on Biogen Idec's MS superstar Tecfidera

Biogen Idec's ($BIIB) multibillion-selling multiple sclerosis drug Tecfidera is grabbing market share left and right, but Denmark's Forward Pharma says it has a plan to take on the monster seller with its own product. It says it is looking at a $200 million IPO in the U.S. to raise money to do clinical trials--but it will spend some of the money for an IP fight against the U.S. drugmaker. Story | More

 

Suggested Articles

Not even two months into a probe of officials accused of taking Novartis bribes, Greece's parliament is handing off the investigation.

A U.S. appeals court called Maryland's groundbreaking price-hike law unconstitutional, sending legislators back to the drawing board.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.